Market closed

Nurix Therapeutics/$NRIX

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Nurix Therapeutics

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Ticker

$NRIX
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
San Francisco, United States

Employees

284
Website
www.nurixtx.com

NRIX Metrics

BasicAdvanced
$1.3B
-
-$2.89
2.22
-

$1.3B

2.22

$27.37

$7.65

831K

5.285

5.201

5.464

7.202

-29.46%

-57.96%

20.621

3.38

3.38

-10.884

-17.76%

5.29%

24.78%

6.38%

What the Analysts think about NRIX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Nurix Therapeutics stock.

NRIX Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

NRIX Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

NRIX News

AllArticlesVideos
Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation

Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation

Seeking Alpha·6 days ago
Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewsWire·1 week ago
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia

GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NRIX

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Nurix Therapeutics stock?

Nurix Therapeutics (NRIX) has a market cap of $1.3B as of January 15, 2025.

What is the P/E ratio for Nurix Therapeutics stock?

The price to earnings (P/E) ratio for Nurix Therapeutics (NRIX) stock is 0 as of January 15, 2025.

Does Nurix Therapeutics stock pay dividends?

No, Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Nurix Therapeutics dividend payment date?

Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders.

What is the beta indicator for Nurix Therapeutics?

Nurix Therapeutics (NRIX) has a beta rating of 2.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.